PAR Paradigm Biopharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.17
52wk 0.14 – 0.47
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$104.86M
P/E (trailing)
—
P/E (forward)
-2.11
EPS (trailing)
-0.10
Dividend yield
—
Payout ratio
0.0%
Beta
-0.01
EV / EBITDA
-1.69
Price / Book
12.50
ROE
-180.2%
Operating margin
-86,793.9%
Net margin
0.0%
Total cash
$14.74M
Total debt
$9.38M
Current ratio
1.30
Debt / Equity
1.56
Free cash flow
$-17.95M
Avg volume
1.84M
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.06
- Free cash flow—
- Net debt—